Takeda Pharmaceutical

TAK

Market cap $48.1B

BOSTON--(BUSINESS WIRE)---- $TAK #antitrust--A class-action lawsuit regarding Amitiza ended today when a jury found Takeda Pharmaceuticals liable for $474 million, according to Hagens Berman.

A ​U.S. jury on ‌Monday found that ​Takeda ​Pharmaceutical caused pharmacies, ⁠insurers, ​retailers and ​others to sustain about $885 million ​in ​damages delaying the ‌release ⁠of a generic version of ​its ​anti-constipation ⁠drug Amitiza ​through an ​anticompetitive ⁠scheme.

TAK's FY2025 revenue was about $28.4 billion, which was down 1.7% YoY due to Vyvanse's generic pressure. This remains a growth headwind until their first wave launches. Management is pairing a new transformation program with cost-cutting measures that will target over $1.3 billion in annualized gross savings by FY2028. As such, I believe TAK's long-term bull case depends on three near-term launch candidates (i.e., the first wave) with oveporexton, rusfertide, and zasocitinib.

Takeda Pharmaceutical NYSE: TAK reported fiscal 2025 results that management described as solid despite pressure from generic competition to VYVANSE, while outlining a transition plan built around three expected product launches and a broader cost transformation program.

Japan's Takeda Pharmaceutical , plans to cut about 4,500 jobs in fiscal year 2026, as it pushes ahead with ​a restructuring to centralize corporate functions and reduce ‌costs.

Takeda Pharmaceutical Company Limited (TAK) Q4 2026 Earnings Call Transcript

OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for the fiscal year 2025 (period ended March 31, 2026). The Company delivered solid results in line with its latest FY2025 Management Guidance, reflecting strong OPEX savings, mitigating revenue headwinds while continuing to invest in future growth. Key Highlights for FY2025 Revenue decreased by 1.7% YoY at actual exchange rates (AER), resulting from the loss of exclusivity for VYVANSE® which was parti.

Takeda Pharmaceutical ​said its ‌experimental drug ​for ​primary immunodeficiency disease, ⁠a ​rare condition ​that weakens the ​immune ​system, has met ‌the ⁠main goal of a ​mid- ​to ⁠late-stage ​clinical trial.

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in Primary Immunodeficiency Disease (PID) patients, met its primary endpoint.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.